Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 19 years and older~* Those who are able to comply with the requirements for the study~* If women, a negative pregnancy test and willingness to use birth control measures for the entire study duration~Exclusion Criteria:~* Disorders in immune function~* Any malignancy or lymphoproliferative disorder~* History of Guillain-Barré syndrome~* Individuals with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time~* Experience of fever (\>38.0 ℃) within 24 hours following vaccination~* Body temperature \>38.0 ℃ at the vaccination day~* Concomitant medications/therapy such as immunosuppressants or immune modifying drugs, systemic corticosteroids, immunoglobulins, blood or blood- derived products within 3 months~* Influenza vaccination within 6 months~* Subjects who have participated in other interventional study within 4 weeks~* Any vaccination within 1 month~* Those who are planning to receive any vaccine within 1 month from the study vaccine~* Individuals with any serious chronic or progressive disease~* Pregnant or breast-feeding women~* Any other reason that in the opinion of the investigator might interfere with the study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- NBP607-QIV (Type: EXPERIMENTAL): Participants aged 19 years and older received a 0.5mL single intramuscular dose of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria on Day 0
- NBP607-Y (Type: ACTIVE_COMPARATOR): Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata on Day 0
- NBP607-V (Type: ACTIVE_COMPARATOR): Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria on Day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).